This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.A melanocyte master regulatory gene called MITF (Micro-phthalmia-associated transcription factor) was found to be amplified in progressive melanomas. MITF amplification was more prevalent in metastatic disease and correlated with decreased overall patient survival. Since the melanoma cells with amplified MITF are highly resistant to chemotherapy, a different approach utilizing the power of immunotherapy will be enlisted to evaluate whether an alternative strategy may prove useful in therapy or as a marker for progressive melanoma. The role of the volunteers and patients will be to donate blood, which will be surveyed using peptides derived from the MITF gene that have been determined using bioinformatics approaches. These peptides will be used in flow cytometry studies to determine whether there is immune recognition of this gene product and whether the recognition is present in both healthy volunteers and melanoma patients with different stages of the disease.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000043-48
Application #
7716662
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2008-04-20
Project End
2008-11-30
Budget Start
2008-04-20
Budget End
2008-11-30
Support Year
48
Fiscal Year
2008
Total Cost
$10,816
Indirect Cost
Name
University of Southern California
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Kelsey, Megan M; Braffett, Barbara H; Geffner, Mitchell E et al. (2018) Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. J Clin Endocrinol Metab 103:2309-2318
Davis, J N; Asigbee, F M; Markowitz, A K et al. (2018) Consumption of artificial sweetened beverages associated with adiposity and increasing HbA1c in Hispanic youth. Clin Obes 8:236-243
Kleinberger, Jeffrey W; Copeland, Kenneth C; Gandica, Rachelle G et al. (2018) Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med 20:583-590
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2018) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes 19:191-198
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44
Venditti, E M; Tan, K; Chang, N et al. (2018) Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes. Diabetes Res Clin Pract 139:24-31
Detterich, Jon A (2018) Simple chronic transfusion therapy, a crucial therapeutic option for sickle cell disease, improves but does not normalize blood rheology: What should be our goals for transfusion therapy? Clin Hemorheol Microcirc 68:173-186
Gidding, Samuel S; Bacha, Fida; Bjornstad, Petter et al. (2018) Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr 192:86-92.e5
Manosroi, Worapaka; Tan, Jia Wei; Rariy, Chevon M et al. (2017) The Association of Estrogen Receptor-? Gene Variation With Salt-Sensitive Blood Pressure. J Clin Endocrinol Metab 102:4124-4135
Cooper, Aaron R; Lill, Georgia R; Shaw, Kit et al. (2017) Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients. Blood 129:2624-2635

Showing the most recent 10 out of 565 publications